Trials / Completed
CompletedNCT01977755
Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 591 (actual)
- Sponsor
- Zealand Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study explores the potential cardioprotective properties of danegaptide when administered to patients with ST-Segment elevation myocardial infarction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | danegaptide | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2015-12-20
- Completion
- 2016-06-08
- First posted
- 2013-11-07
- Last updated
- 2018-04-06
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01977755. Inclusion in this directory is not an endorsement.